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Sllmmal~ 
Serum autoantibodies from a patient with autoantibodies directed against the Golgi complex 
were used to screen clones from a HepG2 XZ_ap cDNA library. Three related clones, designated 
SY2,  SY10, and SYll, encoding two distinct polypeptides were purified for further analysis. 
Antibodies affinity purified by adsorption to the XZ_ap-cloned  recombinant proteins and antibodies 
from NZW rabbits immunized with purified recombinant proteins reproduced Golgi staining 
and bound two different proteins, 95 and 160 kD, from whole cell extracts.  The SYll protein 
was provisionally named golgin-95 and the SY2/SY10 protein was named golgin-160. The deduced 
amino acid sequence of the cDNA clone of SY2 and SYll represented 58.7- and 70-kD proteins 
of 568 and 620 amino acids. The in vitro translation products of SY2 and SYll cDNAs migrated 
in SDS-PAGE at 65 and 95 kD, respectively.  The in vitro translated proteins were immunoprecipitated 
by human anti-Golgi serum or immune rabbit serum, but not by normal human serum or 
preimmune rabbit serum. Features of the cDNA suggested that SY11 was a full-length clone 
encoding golgin-95 but SY2 and SY10 together encoded a partial sequence of golgin-160. Analysis 
of the SY11 recombinant protein identified a leucine zipper spanning positions 419-455, a glutamic 
acid-rich tract spanning positions 322-333, and a proline-rich tract spanning positions 67-73. 
A search of the SwissProt data bank indicated sequence similarity of SYll to human restin, the 
heavy chain of kinesin, and the heavy chain of myosin. SY2 shared  sequence similarity with 
the heavy chain of myosin, the USO1 transport protein from yeast, and the 150-kD cytoplasmic 
dynein-associated polypeptide. Sequence analysis demonstrated that golgin-95 and golgin-160 
share 43%  sequence similarity and, therefore,  may be functionally related  proteins. 
H 
uman autoantibodies have proven to be useful reagents in 
elucidating the structure and function of eucaryotic or- 
ganelhs. For example, naturally occurring autoantibodies have 
been used to identify and clone chromatin, nucleolar,  nu- 
clear envelope, and cytoplasmic proteins (reviewed in refer- 
ences 1-3). Antibodies directed against the Golgi complex 
have been reported in the sera of patients with SLE (4), 
Sj6gren's  syndrome and other systemic rheumatic diseases 
(4-9), idiopathic cerebellar ataxia (10), paraneoplastic  cere- 
bellar degeneration (11), and viral infections, including the 
EBV (12), and HIV (13). This study reports the identification 
and cloning of two Golgi autoantigens that react with au- 
toantibodies in the sera of patients with autoimmune diseases. 
The Golgi apparatus is a complex cytoplasmic organelle 
that has a prominent function in the processing, transporting, 
and sorting of intracellular proteins (14, 15). Structurally,  the 
Golgi complex is localized in the perinuclear region of most 
mammalian cells and is characterized by stacks of membrane- 
bound cisternae as well as a functionally distinct trans-Golgi 
network (16, 17). The intraceUular transport of newly syn- 
thesized and recycled proteins requires directed movement be- 
tween the endoplasmic reticulum, the intracdlular vesicles 
to the c/s, medial, and trans compartments of the Golgi com- 
plex, and the plasma membrane (15, 18, 19). The signals and 
molecular characteristics of the proteins that control this in- 
tracellular traffic are poorly understood, but it is known that 
intraceUular microtubules are important structural and func- 
tional components (20,  21). Constituent and resident pro- 
teins of the Golgi complex bdieved to play a role in these 
processes include families of Proteins such as the adaptins (22), 
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GTP-binding proteins (26), including ADP ribosylation factors 
(ARFs) (27,  28),  and resident enzymes (reviewed  in refer- 
ence 14). 
Although the Golgi complex has been identified as a target 
of autoantibodies for almost a decade, little is known about 
the antigenic targets or the events that lead to the induction 
of anti-Golgi antibodies. An attractive feature to the study 
of Golgi antigens is the knowledge that viruses,  including 
HIV (29), coronaviruses (30), rubella (31), and various others 
(reviewed in reference 32), are processed in, and disrupt (33, 
34),  the Golgi complex. Observations that certain viruses 
induce anti-Golgi antibodies in mice (35, 36), and that indi- 
viduals infected with EBV (12) and the HIV-I virus (13) bear 
anti-Golgi antibodies, add incentive to the study of the mo- 
lecular characteristics  of the Golgi autoantigens. 
In this study, we have used the antibodies from a patient 
with SLE to clone and characterize two distinct Golgi au- 
toantigens. Studies of the characteristics of these proteins and 
the effects of brefeldin A (BFA) on their intracellular distri- 
bution suggest that the proteins are related to the coatomer 
proteins and may belong to a family of myosin-like mole- 
cules. The molecular features of these proteins suggest that 
they have a unique function in the processing and transport 
of proteins through the Golgi complex. 
Materiah and Methods 
Human Sera.  Sera  from patients with Golgi autoantibodies  were 
obtained from serum banks at the University of Calgary (Calgary, 
Alberta), The Scripps Research Institute (La Jolla, CA), and Im- 
muno Concepts Inc. (Sacramento, CA). The serum samples were 
stored at -20 or -70~  The specificity  of  the autoantibodies for 
Golgi antigens was first identified on the basis of indirect im- 
munofinorescence  (IIF) microscopy  (4). Control sera were randomly 
selected from a bank of 2,000 female Red Cross blood donors (37) 
or sera pooled from healthy volunteers. 
Cell Lines.  HeLa (ATCC CCL 2.2; American Type Culture 
Collection, Rockville,  MD); MOLT-4 (human T cell lymphobhstic 
leukemia; ATCC CRL 1582); HEp-2 (human epidermoid carci- 
noma ceils), and HepG2 (human hepatic carcinoma, ATCC HB 
8065) cells  were maintained  in RPMI 1640 supplemented  with 10% 
FCS, 2 mM t-glutamine, and 5/~g/ml gentamycin sulfate. 
Indirect Immunafluorescence.  IIF was performed on cells grown 
on teflon-masked  slides or commercially  prepared HEp-2 cell sub- 
strates (Immuno Concepts Inc.) using a fluorescein-conjugated  goat 
anti-human IgG (light and heavy chain) as previously described 
(38, 39). Double-hbeling and colocalization studies used TRITC- 
conjugated wheat germ agglutinin (Sigma  Chemical  Co., St. Louis, 
MO)  and rhodamine-conjugated goat anti-rabbit  IgG (Pierce, 
Rockford, IL). Slides were viewed with a microscope fitted with 
epifinorescence (Carl Zeiss, Inc., Thornwood, NY) or a confocal 
scanning laser microscope equipped with a krypton-argon light 
source (MRC600; Bio-Rad Laboratories, Richmond,  CA). 
Immunoelectron Micmscolv.  Human HEp-2 cells were grown in 
DMEM containing 10% FCS in Lux Permanox dishes (Electron 
Microscopy Sciences, Fort Washington, PA). After 2 d in culture, 
monolayer  cells  were rinsed in PBS, fixed 30 min at room tempera- 
1 Abbreviations used in thispaper: BFA, brefeldin  A; COP, coatomer  protein; 
lie indirect immunofluorescence. 
ture (RT) with 4% electron microscopy-grade  formaldehyde  (Poly- 
sciences, Warrington, PA) buffered with PBS, rinsed with PBS, 
and then permeabilized with 100% acetone for 1 min at  -20~ 
After a rinse in PBS, cells were blocked for 30 min at RT with 
I% BSA/PBS, incubated 1 h at 37~  with the serum SY diluted 
1:200 in 1% BSA/PBS, rinsed three times for 10 min in PBS, blocked 
30 min with 1% BSA/PBS, and then incubated I h at 37~  with 
affinity-purified  goat anti-human IgG coupled  to peroxidase  (Cappel 
Laboratories, Cochranville,  PA) diluted 1/100 in 1% BSA/PBS. Cells 
were then rinsed three times for 10 min in PBS, fixed  30 min at 
RT with 1% glutaraldehyde  buffered  with PBS, rinsed  in PBS, rinsed 
in 50 mM Tris-HC1 (pH 7.6), and then incubated 5 min at RT 
in  1 mg/ml diaminobenzamine/0.03%  HzOz dissolved in  Tris 
buffer and distilled water, and then stained for 30 min with 2% 
OsO4 in distilled water, rinsed in distilled water, dehydrated with 
ethanol, and then embedded in Polybed 812 (Polysciences). Em- 
bedded whole cells were photographed in the light microscope, 
thin sectioned as monolayers, and then examined unstained in the 
electron microscope. 
SDS-PAGE and Immunoblotting.  Proteins  or cellular prepara- 
tions were solubilized in SDS sample buffer and separated by dis- 
continuous SDS-PAGE according to the method of Laemmli (40). 
The separated  proteins were transferred  to nitrocellulose  as described 
by Towbin and Gordon (41) and adapted in our laboratory (42). 
After transfer, nitrocellulose strips were blocked with 3% nonfat 
milk in PBS containing 0.05% Tween-20 (PBST), and then over- 
laid with the primary antibody and washed with PBST to remove 
any unbound antibody.  Bound antibody was traced  with polyvalent, 
peroxidase-conjugated goat anti-human Ig (Calbiochem-Behring 
Corp., La Jolla, CA) or 12sI-protein A (2-4  x  10  s cpm/ml (ICN 
Radiochemicals,  Irvine, CA). Bound antibodies were visualized  by 
incubating the washed nitrocellulose strips in substrate solution 
or by exposing the air-dried nitrocellulose to X-OMAT AR film 
(Eastman Kodak Co., Rochester, NY). 
eDNA Library Screening.  Clones from a HepG2 XZap cDNA 
library were initially screened by an immunological method as 
modified by Young and Davis (43). All screening was performed 
on duplicate filters and positive bacteriophages were subsequently 
purified to 100%. Before  screening  the cDNA library, the sera were 
extensively adsorbed against bacteria and wild-type )~_ap phage 
to reduce background binding. Bound antibodies were detected by 
immunoblotting  as described above. 
DNA  Subcloning and Sequence Determination.  Purified  )~7_ap 
clones were subcloned  in vivo into pBluescript plasmids using R408 
helper phage as recommended in the manufacturer's instructions 
(Stratagene Inc., La Jolla, CA). The nucleotide sequence was de- 
termined using the dye primer cycle sequencing kit and DNA se- 
quencer (373A; Applied Biosystems,  Inc., [ABI], Foster City, CA). 
Oligonucleotide  primers were synthesized  with a DNA synthesizer 
(380B; ABI). DNA sequences  were determined in both strands and 
compiled using the alignment program SeqEd (ABI). 
PCR.  PCR was used to determine the size and orientation of 
cDNA inserts  using methods  essentially  as described  in the GeneAmp 
DNA Amplification Reagent Kit (Perkin Elmer Corp., Norwalk, 
CT). 50- or 100-/~1 reaction volumes  were used and were composed 
of PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCI, 1.0 mM 
MgC12, 0.01% gelatin), dATP, dCTP, dGTP, and dTTP to a final 
concentration of 0.2/~M. Sample DNA was added and solutions 
were heated to 95~  for 5 min, followed  by addition of 2.5 U am- 
plitaq (rTaq DNA polymerase; Perkin Elmer Corp.), and one drop 
of  paraffin  oil DNA amplification  was performed using a microcy- 
cler (Eppendorf Inc., Freemont, CA) with up to 35 cycles of 94~ 
for 30 s; 55~  for 30 s; 72~  for 90 s; and a final 7-rain elongation 
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rated on 1% agarose gds and stained with ethidium bromide to 
visualize PCR products. DNA samples for PCR were obtained 
from phage suspensions or bacterial colonies (44). 
A~inity Purification ofAutoantibodies.  Affanity  purification  of an- 
tibody from kZap dones used confluent plates that were induced 
to produce recombinant protein with isopropyl-thiogalacto-pyrano- 
side (IPTG; Fisher Scientific,  Springfield,  NJ)-impregnated  nitrocd- 
lulose filters. After incubating the plates overnight, the filters were 
blocked and probed with primary antibody and washed as described 
above for immunoblotting.  Bound antibody was ehted from the 
filters with 3 ml ofelution buffer (50 mM KHzPO,, pH 2.5, 150 
mM NaC1, 1.0% BSA) by rocking at room temperature for 5 min. 
The filter was quickly rinsed with an additional 1-ml  dution buffer 
and the eluates were collected and neutralized with 225 ~1 1 M 
"Iris, pH 8.8.  The eluted antibodies were concentrated with a 
microconcentrator (Centricon 100; Amicon Corp., Danvers, MA) 
and used for IIF and immunoblotting analysis. 
In Vitro RNA Transcription  and Translation.  Appropriate  clones 
identified in the screening outlined above were used for in vitro 
transcription and translation  experiments. 1/zg of linearized  plasmid 
DNA was used as template for in vitro transcription with T7 or 
T3 RNA polymerase. RNA transcripts were analyzed in 0.8% 
agarose gel containing 2.2 M formaldehyde. 1 ~g of the transcribed 
RNA was added in a 50-/A translation reaction containing rabbit 
reticulocyte lysate, [3SS]methioniue  (Trans-~SS label, 70% methio- 
nine, 15% cysteiue; ICN Biochemicals, Irvine, CA), and RNase 
block II (Stratagene  Inc.) as suggested  by the manufacturer  (Promega 
Biotec, Madison, WI). Translation was carried out at 30~  for I h 
followed by SDS-PAGE of a 2-5-/zl aliquot to confirm the presence 
of translation products. Samples were stored at  -80~  until re- 
quired. 
lmmunoprecipitation.  Immunoprecipitation  of  ~sS-labeled in 
vitro translation products was performed  using protein A-Sepharose 
beads (45). Briefly, 10 #1 of human serum and 2-5 ~1 of in vitro 
translation product were incubated with protein A-Sepharose beads 
1-2 h at 4~  After incubation, the Sepharose beads were washed 
five  times with buffer and resuspended  in SDS sample  buffer.  Samples 
were then analyzed  by SDS-FAGE.and  autoradiography  as described 
above. 
Recombinant Protein Production.  Plasmids  were transformed in 
Escherichia coil strain XL-1BIue (Stratageue Inc.). The recombinant 
protein was prepared from 200-ml cultures of the recombinant ceils 
grown to OD~  =  0.6 at 37~  and induced with IIrI'G added 
to a final concentration of 10 raM.  After overnight incubation, 
the bacteria were harvested by centrifugation. The recombinant 
protein was enriched by the method of  Adams et al. (46). The final 
pellet of iuclusion bodies was extracted with 1 M urea in 0.1 M 
Tris (pH 7.3) on ice for 1 min to remove  residual  bacterial proteins. 
The inclusion bodies were then pelleted in an Eppendorf microfuge 
at 13,000 rpm and extracted with 8 M urea in 0.1 M Tr/s buffer 
for 15 min on ice. In some experiments, the SYll inclusion  granules 
were extracted with Tris buffer containing 8 M urea, 0.2% 3-mer- 
captoethanol. The supernatants from the extractions were stored 
at -70~  Proteins were separated  by SDS-PAGE and stained with 
Coomassie  blue or transferred  to nitrocellulose  for immunoblotting. 
Rabbit Immunization.  Three New Zealand white rabbits were 
separately  immunized by subcutaneous  and intramuscular injection 
of 1.5 mg of extracted recombinant proteins in an equal volume 
of CFA. 2 wk later, the animals were boosted with 2.0 mg of the 
protein in IFA. The appearance and titer of Golgi antibodies was 
monitored by indirect immunofluorescence  using goat anti-rabbit 
IgG (H + L chain) antibody (Calbiochem-Behring  Corp., LaJoUa, 
CA) as described above. 
BFA.  HEp-2  cells growing under standard  conditions  on teflon- 
masked microscope  slides (Cell-Line  Associates Inc., Newfield, NJ) 
were incubated in 7.5 pM BFA (Sigma Chemical Co., St. Louis, 
MO). Slides were removed from the BFA media after 0, 5, 15, 30, 
and 60 min, washed in ice-cold PBS, then fixed in ice-cold meth- 
anol for 20 rain. In cultures growing in paraUd, the BFA media 
was replenished with fresh media without BFA and slides were 
removed for methanol fixation 90 rain later. Changes to the struc- 
ture and distribution of the Golgi complex antigens were followed 
by indirect immunoperoxidase staining (47) using the prototype 
serum SY, rabbit antibodies to the recombinant SY2, SY10, and 
SYll proteins, and affnity-pufifed  antibodies as described above. 
Computer Analysis of Nucleic Acid and Protein Sequences.  Nucleic 
acid and protein sequences were analyzed  by the University of  Wis- 
consin Genetics Group Sequence Analysis  Software Package (48). 
Alignment of protein sequences was achieved  with the GAP pro- 
gram that used a published  algorithm (49). Multiple sequence  align- 
ments were performed with the CLUSTAL programs (50). 
Results 
Immunofluorescence and lmmunoetectron Microscot~  Nine sera 
that demonstrated the typical IIF pattern for Golgi autoantl- 
bodies (4) on HEp-2 cells were identified. A serum from a 
SLE patient with pericarditis and central nervous system in- 
volvement (SY) was selected for the cloning studies because 
it demonstrated high titer (~>1:2,560) and relatively mono- 
specific staining of the Golgi complex on methanol-fixed 
HEp-2 cells (Fig.  1 a). Analysis of a variety of cell lines, in- 
cluding HepG2.and HeLa cells, revealed similar patterns of 
staining. Fixation of cells in acetone or 1%  paraformalde- 
hyde did not alter the staining pattern. 
Immunoelectron microscopy of HEp-2 cells demonstrated 
that antibodies from the serum SY bound to .juxtanudear 
cisternae of the Golgi complex (Fig.  2,  a  and b).  Further 
confirmation that the antigens were localized to the Golgi 
complex was  demonstrated by colocalization of TRITC- 
conjugated wheat germ agghtinin to the corresponding struc- 
tures stained by the prototype serum (Fig.  2, c and d). 
Immunoblotting.  Immunoblotting of the prototype serum 
(SY) using MOLT-4 cell extracts revealed reactivity with a 
number  of antigens,  including 30-,  95-,  110-, 150-,  and 
160-kD proteins (Fig. 3, lane 1). When additional anti-Golgi 
sera  were  screened  by  immunoblotting  a  heterogeneous 
number of  proteins were recognized. For example, one serum 
(lane 2) bound to the 30-,  150-, and 160-kD proteins, and 
five (lanes 4-8) demonstrated reactivity with the 95-kD and 
other proteins. One serum (lane 4) bound 140- and 150-kD 
proteins and another (lane 9) strongly reacted with proteins 
<60 kD. Other bands of reactivity with the anti-Golgi sera 
included proteins of 40,  50,  60,  110, and 190 kD. 
Cloning and Sequencing of Golgi cDNA.  The prototype 
human serum (SY) reactive with the 160-,  150-,  110-, and 
95-kD Golgi antigens was chosen to screen a HepG2 ~Eap 
expression library. From screening 460,000 plaques,  11 posi- 
tive signals were obtained, 3 of which (SY2,  SY10, SY11) 
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HEp-2 cells. The Golgi  antigen  is identified  as lamellar  and vesicular  struc- 
tures located  outside  the nuclear  membrane.  The single  cell  staining  more 
intensely is in metaphase. (b) Indirect immunofluorescence  of antibody 
ehted from SY11 ~7_~ap  recombinant  protein. Stereo  reconstruction  from 
optical sections of HEp-2 cells recorded  on the confocal  microscope  at 
0.4-#m intervals.  The antibody  is primarily  localized  to the lamellar  stacks 
of the Golgi complex. HEp-2 cells were fixed in methanol. 
retained specificity after secondary and tertiary screening to 
100%  purity. When antibodies from the prototype serum 
were affinity purified on nitrocellulose filters  containing 5 
x  104 phage-expressing SY2  and SYll  recombinant pro- 
teins,  all reproduced the Golgi pattern of immunofluores- 
cence on HEp-2 cells (Fig.  1 b). The stereo reconstruction 
of the staining derived from confocal scanning laser micros- 
copy showed that the antibodies affinity purified from SY11 
clones (Fig. 1 b) bound primarily to the lamellar Golgi stacks 
of HEp2 cells. Some reactivity with vesicular structures was 
also noted. No reactivity with microtubules, intranuclear com- 
ponents,  or the plasma membrane was observed with the 
affinity-purified  antibodies.  A similar pattern of reactivity was 
observed with affinity-purified anti-SY2  (not shown). 
The cDNA inserts were subdoned in vivo into pBluescript 
plasmid,  and both strands were sequenced across the poly- 
linker arms. The nucleotide sequences of the DNA and the 
deduced amino acid sequences of SY2 and SYll  are shown 
in Fig. 4. Our data suggested that SYll encoded a complete 
protein sequence because it contained a 3' poly(A) tail and 
an open reading frame of 620 amino acids  (Fig.  4 a). The 
deduced amino acid sequence of the cDNA clone of SY2 and 
SY11 represented 58.7-  and 70-kD proteins of 568  and 620 
amino acids,  and calculated isoelectric points (pls) of 6.09 
and 4.57, respectively (Table 1). The three clones were found 
to represent two groups of unique sequences with SY2 and 
SY10 having an "~95%  overlap (Figs.  4  b and 5 a). 
A comparison of the length of the cDNA clones and the 
overlap of SY2 and SY10 is illustrated in Fig. 5 a. Analysis 
of the deduced amino acid sequence of SY2 predicted that 
this polypeptide was exclusively an c~-helical structure with 
an absence of/3 sheets (Fig.  5  b).  Similarly, SYll  had pri- 
marily an  o~-helical structure with  some 13  sheet  regions 
identified (Fig.  5 c). Other special features of SYll included 
a leucine zipper (coiled-coil motif) spanning positions 419-455, 
a  glutamic  acid-rich  tract  spanning  positions  322-333,  a 
proline-rich tract spanning positions 67-73, and a single puta- 
tive glycosylation site (Fig.  5 c). Analysis of the sequences 
of  SY2 or SY11 did not disclose any transmembrane domains 
or signal sequences.  Of interest, the amino acid sequence of 
SY2 demonstrated 43% sequence similarity and 22% sequence 
identity with SY11 (Fig.  5 d). 
The nudeotide and deduced amino acid sequences were 
used to search the Genebank, EMBL, and NBKF data banks 
for homologous sequences (Table 1). Up to 21%  similarity 
of amino acid sequences was found with several other reported 
sequences. A search of the SwissProt data bank indicated that 
SY2 and SY11 had "~20% sequence similarity with the heavy 
chain of  myosin from a number of species, including humans. 
The sequence similarity with the heavy chain of myosin is 
distributed  over  a  371-amino  acid  segment  (amino  acids 
163-593  of SYll  and 9-373  of the human heavy chain of 
myosin). SYll  also shared '~20%  sequence similarity with 
the human protein restin and the yeast protein NUM1. SY2 
shared ,o20% sequence similarity with the yeast intracellular 
protein transport protein USO1 and the 150-kD dynein-asso- 
ciated polypeptide. Neither SY2 nor SYll shared significant 
sequence similarity with/3-adaptin, j3-COP, or other known 
mammalian Golgi components. 
Rabbit Antibody to Recombinant Protein.  Further support 
for the authenticity of the cloned cDNA as coding for Golgi 
complex antigens was obtained by analyzing rabbit antisera 
raised against SYll,  SY10,  and SY2 recombinant proteins. 
The resulting antibodies were shown to react in a similar 
manner to the prototype sera by indirect immunofluorescence 
(Fig. 6) and immunoblotting (Fig. 7). Fig. 6 a illustrates the 
immunofluorescence staining pattern on HEp-2 cells of the 
prototype Gotgi serum using a FITC-conjugated anti-human 
IgG reagent. Fig. 6 b shows the anti-Golgi reactivity of rabbit 
sera  after immunization with  recombinant protein  SY11. 
Double staining with fluorescein anti-human and rhodamine 
anti-rabbit IgG showed overlap of the staining patterns. Simi- 
larly, rabbits immunized with the SY2 or SY10 recombinant 
proteins demonstrated high titer (>1:3,000)  anti-Golgi re- 
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scopic localization of SY antibody re- 
activity in a monolayer of HEp-2 cells. 
(a) By immunoe]ectron microscopy, an- 
tibody is localized  specifically in  the 
Golgi  (G)  complex  cisternae  (arrow- 
heads); (N) nucleolus;  x 7,800. (b) By 
whole cell light microscopy, the per- 
axidase staining is confined to thejux- 
tanuclear Colgi complex (arrowheads); 
x 500. The antibody reactivity  of the 
prototype serum colocalized  to the same 
perinuclear and cytoplasmic structures 
(c)  that  were  stained  by  TRITC- 
conjugated wheat germ agglutinin  (d); 
x400. 
activity by IIF (Fig.  6 d) in a pattern that overlapped com- 
pletely with the human antibody (Fig.  6 c). 
Immunoblotting of HepG2 cellular extract with rabbit an- 
tisera showed reactivities similar to that produced by human 
serum (Fig.  7). The antibodies from the rabbit immunized 
with SY10 reacted specifically with the 160-kD antigen in 
HepG2 extract (Fig.  7, lane I). This band has the same mo- 
lecular mass as the one identified by the prototype serum in 
MOLT4 cell extracts (Fig. 3, lane 1) and in HepG2 extracts 
(Fig.  7, lane 2). Of interest, the serum from the rabbit im- 
munized with the SY10 recombinant protein also reacted with 
the 160-kD protein (Fig. 7, lane 5) and several other proteins 
of 110, 90, 50, and 36 kD. The rabbits immunized with recom- 
binant SY11 protein produced strong reactivity with a 95- 
kD protein but also weaker reactivity with >200-, 85-, and 
75-kD proteins (Fig.  7, lane 3). The >200-, 95-, and 88-kD 
proteins in Hep-G2 cell extracts were also identified by the 
prototype serum (Fig.  7, lane 2). Rabbit sera 2 wk after im- 
munization with SY10 (Fig.  7,  lane 4) showed weak reac- 
tivity with  some of the same proteins,  as did the rabbit- 
immune serum (Fig. 7, lane 5). Preimmune rabbit serum (Fig. 
7, lane 6) and normal human serum (Fig.  7, lane 7) did not 
react with any proteins. 
In Vitro Translation and Immunolmcipitation.  The 35S-labeled 
53  Fritzler  et al. Figure 3.  Immunoblotting  profile  of anti-Golgi sen. MOLT4  whole 
cell extract  was separated  by 12.5% gel SDS-PAGE,  transferred  to nitrocel- 
lulose, and probed  with serum  dilutions of 1:100. Lanes  I-9 show reac- 
tivity  with anti-Golgi  sera  and lane  10 shows  reactivity  of  normal  control 
serum. Lane 1 shows the reactivity  of the prototype serum SY used to 
screen the HepG2 library. Molecular  mass markers  are indicated  on the 
left. Dots indicate  the positions of the 160-kD golgin-160  and the 95-kD 
golgin-95 proteins. 
in vitro translation product of SYll cDNA migrated in SDS- 
PAGE at 95 kD (Fig.  8 b, lane I) and was immunoprecipi- 
tated by the original human anti-Golgi serum (Fig. 8 b, lane 
3). The in vitro translation product of SYll was also immu- 
noprecipitated by rabbit antisera raised against the SY11 recom- 
binant protein (Fig. 8 b, lane 4). Another anti-Golgi serum 
(Fig.  3, lane 2) that reacted with the 160- and 150-kD but 
not the 95-kD proteins did not precipitate the 95-kD in vitro 
translated product (Fig.  8 b, lane 2).  On the other hand, a 
serum that reacted with the 160- and 95-kD proteins (Fig. 
3, lane 3) immunoprecipitated the 95-kD in vitro translated 
products (Fig. 8 b, lane 5). These data supported the immu- 
noblotting results in which sera that reacted with the cel- 
lular 95-kD antigen also tmmunopredpitated the in vitro trans- 
lated  SY11 protein.  These  observations  also  support  the 
conclusion that SYll encodes a full-length protein. Evidence 
that the rabbit antiserum raised by immunization with recom- 
binant SY11 recognized the same protein as the prototype 
human serum was shown when the rabbit antiserum immu- 
noprecipitated the in vitro translation product in an identical 
manner to human Golgi sera (Fig.  8 b, compare lanes 3 and 
5  with lane 4). 
By comparison, the in vitro translation product of SY2 
migrated in SDS-PAGE  at 65 kD (Fig.  8 a, lane 1) and was 
immunoprecipitated by serum from rabbits immunized with 
SY2  (Fig.  8 a,  lanes 3  and 4) and SY10 (Fig.  8 a,  lanes  6 
and 7), but not by preimmune rabbit serum (Fig.  8 a, lanes 
2 and 5). The prototype serum (Fig. 8 a, lane 8) and another 
anti-Golgi serum (Fig.  8 a, lane 9) also did not precipitate 
the SY2 in vitro translation product.  The lower molecular 
mass translation products of SY2 also appeared to be specifically 
immunopredpitated by the immune rabbit sera,  indicating 
the presence of at least one epitope in these smaller fragments. 
The observation that rabbits immunized with SY2 or SY10 
immunoprecipitated the in vitro translation product of SY2 
is in agreement with the conclusion that there was ",~95% 
overlap of the SY2  and SY10 clones. The reason why the 
prototype human serum or other anti-Golgi sera did not im- 
munoprecipitate the in vitro translated SY2 product is not 
clear. For example, the recombinant proteins produced by SY2 
and SY11 in E. coli were reactive with anti-Golgi sera previ- 
ously shown to recognize golgin-160 and golgin-95 in whole 
cell extracts (Fig.  8, c and d, lane I).  The prototype serum 
(Fig.  7 d and 8 c, lane 2), affinity-purified antibodies to SY2 
(Fig. 8 c, lane 3) and SY11 (Fig. 8 d, lane 3), and rabbit serum 
raised against SY2  (Fig. 8 c, lane 4) and SY 11 (Fig.  8, d, 
lane 4) also reacted with the recombinant protein. Normal 
human serum (Fig. 8, c and d, lane 5) and preimmune rabbit 
serum (data not shown) did not react with the purified recom- 
binant proteins. The data suggest that the epitopes critical 
for human antibody binding are present on the recombinant 
protein derived from the original X phage and the subcloned 
pBluescript plasmid but that they are not present on the in 
vitro transcribed and translated protein. 
BFA.  Our attention turned to possible relationships of 
the cloned proteins to the coatomer protein fl-COP. BFA, 
an isoprenoid fungal antibiotic, is known to have an early 
and characteristic effect on fl-COP and other coatomer pro- 
teins of the Golgi complex (15,  51, 52). Intermediate con- 
centrations (7.5/~M) of the drug were used to study the effects 
on the Golgi antigens identified by the prototype serum and 
the rabbit antisera raised against recombinant proteins. At 
0 and 2 min, the Golgi staining remained typical of  untreated 
cells (Fig. 9, a and b). However, 5 and 10 min after exposure 
of HEp2 cells to the drug, there is a remarkable reduction 
of staining in the perinuclear Golgi complex and the appear- 
ance of  vesicular and elongated microtubular structures (Fig. 
9, c and d). At 30 min, there is complete loss of Golgi staining 
(e) that  is restored 90 min after removal of the drug (~. 
Discussion 
This work is aimed at characterizing and identifying the 
Golgi complex autoantigens that are the targets of autoanti- 
bodies in the sera of patients with autoimmune diseases. To 
begin analysis of  the Golgi complex, we have cloned the cDNA 
encoding the complete protein sequence of a 95-kD autoan- 
tigen identified by a SLE serum, and have named this golgin- 
95. We also obtained a cDNA encoding a portion of a second 
54  Cloned  Golgi Complex Autoantigens a 
I TA__._~ATCAGGGGCTGGTAATGGAGTCGGTTAGACAACTACAAATGGAGAGAGATAAATAT  GC~~AT  GT~T~A~T  G~A~G 
1  M  E  S  V  R  Q  L  Q  M  E  R  D  K  Y  A  E  N  L  K  G  E  S  A  M  W  R  Q  R  M  Q  Q  M  S  E 
121 CAGGTGC~JCACATTGAGAGAGGAGAAGGAATGTAGCATGAGTCGGGTACAGGAGCTGGAGACGAGCTT~T~~T~~A~CA~ 
35  Q  V  H  T  L  R  E  E  K  E  C  S  M  S  R  V  Q  E  L  E  T  S  L  A  E  L  R  N  Q  M  A  E  P  P  P  P  E  P  P  A 
241 GC-GCCCTCCGAGGTGGAGCAGCAGC TACAAGCGGAGGCTGAGCACCTGC GGAAGGAGCT  ~A~A~A~T~~G 
75  G  P  S  g  V  g  Q  Q  L  Q  A  E  A  E  H  L  R  K  E  L  g  G  L  A  G  Q  L  Q  A  Q  V  Q  D  N  E  G  L  S  R  L 
361 AACCGGGAGCAGGAGGAGAGGCTGCTGGAGCTGGAGCGGGCGGCCGAGCTCTGGGGGGA~A~A~~T~A~CC~CA~A~ 
115  N  R  E  Q  E  E  R  L  L  g  L  E  R  A  A  g  L  W  G  E  Q  A  g  A  R  R  Q  I  L  E  T  M  Q  N  D  R  T  T  I  S 
481 CGCGCACTCTCCCAGAACCGGGAGCTCAAGGA(ICAGCTGGCTGAGCT  C~AGAGCGGATTTGT~T  ~T~AT~TC~  ~ET~AGTC~ 
155  R  A  L  S  Q  N  R  E  L  K  E  Q  L  A  E  L  Q  S  G  F  V  K  L  T  N  E  N  M  E  I  T  S  A  L  Q  S  E  Q  H  V 
601 AAGAGGGAGCTGGGA~GAAGCT GGGCGAGCTGCAGGAGAAGCTGAGCGAGCTGAAGGA~GGTGGAGCTGAA~TC~T~A~A~A~CA~G 
195  K  R  E  L  G  K  K  L  G  E  L  Q  E  K  L  S  E  L  K  g  T  V  E  L  K  S  Q  E  A  Q  S  L  Q  Q  Q  R  D  Q  Y  L 
721  GGACACCTGCAGCAGTATGTGGCCGCCTATCAGCAGCTGACCTCT  GAGAAGGAGGTGCTC-CATAATCAGCTACTGCTGCAGACCCAGC  ~GT~A~A~A~AG 
235  G  H  L  Q  Q  Y  V  A  A  Y  Q  Q  L  T  S  E  K  E  V  L  H  N  Q  L  L  L  Q  T  Q  L  V  D  Q  L  Q  Q  Q  E  A  Q 
841  GGCAAAGCGGTGGCCGAGATGGCCCGCCAAGAGTTGCAGGAAACCCAGGAGCGCCT  GGAAGCTGCCACCCAGCAGAA~  ~AGTT~AT~TC~ 
275  G  K  A  V  A  E  H  A  R  Q  s  5  Q  E  T  Q  E  R  L  E  A  A  T  Q  Q  N  Q  Q  L  R  A  Q  L  S  L  M  A  H  P  G 
961  GAAGGAGATGGACT  GGACCGGGAGGAGGAGGAGGATGAGGAGGAGGAGGAGGAGGAGGCGGTGGCAGT~A~T~C~A~~~TG 
315  E  G  D  G  L  D  R  E  E  E  s  D  E  E  E  s  s  s  s  A  V  A  V  P  Q  P  M  P  S  I  P  s  D  L  E  S  R  s  A  H 
1081  GTGGCATTTTTCAACTCAGCTGTAGCCAGTGCC GAGGAGGAGCAGGCAAGGCTACGT GGGCAGCTGAAGGAGC~T~T~T~A~T  ~T~ TC~AG 
355  V  A  F  F  N  S  A  V  A  S  A  g  g  E  Q  A  R  L  R  G  Q  L  K  g  Q  R  V  R  C  R  R  L  A  H  L  L  A  S  A  Q 
1201 AAGGAGCCTGAGGCAGCAG~AGCCCCAGGGACC  GGGGGTGATTCTGTGTGTGGGGAGACCCACCGGGCCCTGCAGGG~T~A~  ~TAT~ATG 
395  K  E  P  s  A  A  A  P  A  P  G  T  G  G  D  S  V  C  G  s  T  H  R  A  L  Q  G  A  M  E  K  T.  Q  S  R  F  H  E  L  M 
1321 CAGGAGAAGGCAGACCTGAAGGAGAGGGTAGAGGAACTGGAACATCGCTGCATCCAGCTTTCTGGAGAGACAGACACCATT  GGA~GTACA~T~A~AGA~A~A~  G 
435  Q  E  K  A  D  v.  K  E  R  V  E  E  L  E  H  R  C  I  Q  L  S  G  E  T  D  T  I  G  E  Y  I  A  L  Y  Q  S  Q  R  A  V 
1441 CTGAAGGAGCGGCACCGGGAGAAC-GAGGAGTA~ATCAGCAGGCTGGC~AAGACAAGGAGGAGATGAA~T~T~T~~~~ 
475  L  K  s  R  H  R  E  )  E  E  Y  I  S  R  L  A  Q  D  K  g  E  M  K  V  K  L  L  E  L  Q  E  L  V  L  R  L  V  G  D  R 
1561 AACGAGTGGCATGGCAGATTCCTGGCAGCTC-CCCAGAACCCTGCT  GATGAGCCCACTTCAGGGGCCCCAGCCCCCCAGGAA~T~T~A~A~T  ~T~GA~TG 
515  N  E  W  H  G  R  F  L  A  A  A  Q  N  P  A  D  E  P  T  S  G  A  P  A  P  Q  g  L  G  A  A  N  Q  Q  G  D  L  C  g  V 
1681 AGCCTCGCCGGCAGTGTGGAGCCTGCCCAAGGAGAGGCCAGGGAGGGTTCTCCCCGT  GACAFECCCACT  GCACA~A~AT~A~GT  ~T~A~  ~  ~ 
555  S  L  A  G  S  V  E  P  A  Q  G  s  A  R  E  G  S  P  R  D  N  P  T  A  Q  Q  I  M  Q  L  L  R  E  M  Q  N  P  R  g  R 
1801 CCAGGC  TTGGGCAGCAACCCCTGCATTCCTTTT TTTTACCGGGCT  GACGAGAATGAT  GAGGTGAAGATCACTGTCATCTAAAAGCCGGCTACTGTCAGC~CT~GT~T 
595  P  G  5  G  S  N  P  C  I  P  F  F  Y  R  A  D  E  N  D  s  V  K  I  T  V  I --C-620 
1921  GGATACCCTGCCCCCACCATATCCCTACCATCCC TTCTCAGTCAACCCTTTACCCTTACAGTAGCAAGCATAGACCCCT  GTCTAACGGGGGTAGACAGGTGCAGATGAGGTGAA~TCAC 
2041  TGTCATCTAAAA(ICTGGCCACTAAATT  2080 
~SYIO  -1, Su  (1) 
i GAGCAAGGAAGATTCAGGACAGGGGACTCCGCGGCTTTGCAGGC  GGTCAAGAGTGGCAAGGA~A~~~~G~T 
I  E  Q  G  R  F  R  T  G  D  S  A  A  L  Q  A  V  K  S  G  K  E  g  L  D  R  G  A  R  R  L  E  E  G  T  g  E  T  S  E  T 
121 TTAGAGAAGTTAAGAGAAGAATTAGCTATCAAATCCGGCCAGGT  GGAACACCTGCAGCAGGAGACTGC~~T~T~CAGT~G 
41  L  E  K  L  R  E  E  L  A  I  K  S  G  Q  V  E  H  L  Q  Q  E  T  A  A  L  K  K  Q  M  Q  K  I  K  E  Q  F  L  Q  Q  K 
241 GTGATGGTGGAGGCCTACCGGCGC GACGCCACCTCCAAAGACCAGCTCATCAGTGAGCTGAAAGCCACCAGGAA~T~~~A~T~ 
81  V  M  V  g  A  Y  R  R  D  A  T  S  K  D  Q  L  I  S  E  L  K  A  T  R  K  g  L  D  S  g  L  K  E  L  R  Q  g  L  M  Q 
361 GTGCACGGGGAGAAGCGGAC~  GAGGCGGAGCTCTCGCGCCTGCACAGAGAGGTGGCCCA~A~AT~TT~A~AG~A~ 
121  V  H  G  g  K  R  T  A  g  A  E  L  S  R  L  H  ]%  g  V  A  Q  V  R  Q  H  M  A  D  L  E  G  H  L  Q  S  A  Q  K  E  R 
481 GACGAGATGGA~CACTT~GTCGTTGCAGTTCGATAAGGAGCAGATGGTCGC~'GTCACAGA~T~~C~~A~~G 
161  D  g  M  E  T  H  L  Q  S  L  Q  F  D  K  E  Q  H  V  ;%  V  T  E  A  N  E  A  L  )  K  Q  I  E  E  L  Q  Q  E  A  R  K 
601 GCCATC~CGGAACAGA~G~AGATGAGGCGGCTGGGCTCAGACTTGACCAGCGCCCAGAAGGAGATGAA~AT~TAC~C~A~A~ 
201  ;%  I  T  E  Q  K  Q  )~  M  R  R  L  G  S  O  L  T  S  A  Q  K  E  H  K  T  K  H  K  A  Y  E  N  A  V  G  I  L  S  R  R 
721 CTGCAGGAGGCCCTCGCGGCCAAGGAGGCTGCGGACGCGGAGCTGGGCCAGCTCCGAGCCCAGGGT~A~A~T  ~AT~T~T~G 
241  L  Q  g  A  L  A  A  K  g  A  A  D  A  g  L  G  Q  L  R  A  Q  G  G  S  S  D  S  S  L  A  L  H  E  R  I  Q  A  L  g  A 
841 GA(~CTGCAGGCTGTCAGTCATAGCAAGACGCTGCTGG~GGA~AGGAGGTCATAGCGCTGACCAGCCAGGA~G~~T~T~C~G 
281  E  L  Q  A  V  S  H  S  K  T  L  L  E  K  E  L  Q  E  V  I  A  L  T  S  Q  E  L  E  E  S  R  E  K  V  L  E  L  E  D  E 
961 CTTCAAGAATCCAGAG~AG~GAAGATAAAACGCCTTGA  .GA~TTGAATTAGAGCACGAGAAAGGGAAGCTTACGGGCCTCGGTCAGTCCAACGCA 
321  L  Q  E  S  R  G  F  R  K  ](  I  K  R  L  E  E  S  N  K  K  L  A  L  E  L  E  H  g  )  G  K  L  T  G  L  G  Q  S  N  A 
1081 GCTCT(~CGGG~JCAA~AGCATCCTAGAAACAGCTTTGGCCAAGAGGGAGGCAGACCTAGTCCAGTTGAACCTT~AGGT~A~AG~~~AG 
361  A  L  R  E  H  N  S  I  L  E  T  A  L  A  )  R  E  A  P  L  V  Q  L  N  L  Q  V  Q  A  V  L  Q  R  K  E  E  E  D  R  Q 
1201 ATGAAGCATCTTGTCCAGGCCCTGCAGGCCTCACTAGAGAAGGAGAAGGAGAAGGTGAACAGCCTCAAGGAGCA~T~T~AT~A~ 
401  M  K  H  L  V  Q  A  L  Q  A  S  L  g  K  E  K  E  K  V  N  S  L  K  g  Q  V  A  A  A  K  V  E  A  G  H  N  R  R  H  F 
1321 AAGGCG~GGAGCTGAGTGAGGTGAAGAAGGAGCT(~CAGGCCAAGGAACACCTGGTGCA~C~GA~A~~A~AG 
441  K  A  A  S  L  g  L  S  E  V  K  K  E  L  Q  A  K  g  H  L  V  Q  K  L  O  A  E  A  D  D  L  Q  I  g  E  G  K  H  S  Q 
1441 GAGATAGCACAGTTCCAAGCAGAGCTGGCCGAGGCCCGGGCACAGCTCCAGCTCCTGCAGAAGCAGCTC.GACGA~A~TCA~CA~CGT  ~~T~ 
481  E  I  A  Q  F  Q  A  ~  L  A  g  A  R  A  Q  L  Q  L  L  Q  K  Q  L  D  E  Q  L  S  K  Q  P  V  G  N  Q  g  H  g  N  L 
~SYI0  1585 
1561 AAATC~GGTGGATCAGA~GAGAAATCCAGTCCTTGAAGCAGCAGCTGGACTTGACGGAGCAGCAGGGCAGGAAGGAACTGGAAGC-~T~A~T  ~T~A~C  G~G 
521  K  W  E  V  D  Q  )  E  R  E  I  Q  S  L  K  Q  Q  L  D  L  T  E  ~  ~  G  R  g  E  L  E  G  L  Q  Q  L  L  Q  N  V  KSY2  11 07 
1681 TCTGAGTTGGAGATGGCCCAGGAAGACCTGTCCATGACCCAGAAGGATAAATTTATGC  1738 
561  S  s  L  E  M  A  Q  E  D  L  S  M  T  Q  K  D  K  F  M  579 
Figare  4.  Nucleotide  and  de- 
duced  amino  add  sequence  of 
cDNA clones SY2, SY10, and SYll. 
Sequencing of both DNA strands 
of each clone was performed with 
custom  synthetic  oligonudeotide 
primers. (a) Sequence of SY11. Un- 
derlined nucleotides are the first up- 
stream in-frame stop codons,  con- 
sensus sequences for the methionine 
start site, and stop codons,  respec- 
tively. Amino acids at 67-73 repre- 
sent  a proline-rich  region,  and at 
322-333  a  glutamic add-rich  re- 
gion. Six beptad repeats of leucine 
(boldface) begin at amino acid 419. 
This  sequence  is  accessible  from 
EMBL/GenBank  under  accession 
number 1.O6147. (b) Combined se- 
quence of SY2 and SY10.  The un- 
derlined nucleotides are the putative 
methionine start sites that are func- 
tional  in  the  in vitro  translation 
system.  The sequences of SY2 and 
SY10 begin at nucleotides  54 and 
1 and terminate at nucleotides 1738 
and  1585,  respectively.  This  se- 
quence  is  accessible from EMBL/ 
GenBank  under accession  number 
1.O6148. 
GolD# complex antigen, named golD#n-160, that reacted with 
the same sera and has a molecular mass of 160 kD. 
The clinical relevance of anti-GolD# antibodies is uncer- 
tain.  It is interesting  that two of the sera with antibodies 
to golgin-160,  including  the serum used to clone the pro- 
tein,  were from patients who had cerebellar disease. Like- 
wise, the report of anti-GolD# antibodies in patients with 
cerebellar ataxia (10), paraneoplastic cerebellar degeneration 
(11), and patients with Sj6gren's syndrome (6) who can de- 
velop central nervous system disease (53,  54) may be clues 
55  Fritzler  et al. 
to the clinical importance and pathogenic role of GolD# anti- 
bodies. 
We considered the possibility that the GolD# antigens that 
we have cloned bear resemblance to GolD# autoantigens de- 
scribed by others. The best characterized GolD# autoantigen 
was recently reported by Kooy et al. (8) as a 230-kD protein 
that was found in both soluble and insoluble fractions of HeLa 
cells. Although this 230-kD GolD#  complex antigen was cloned 
and shown to react with a serum from a Sj6gren's syndrome 
patient,  the sequence has yet to be published. A 65- and a Golgin  cDNAs 
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Fipre  5.  (a) Comparison of the 
recombinant SY2, SY10, and SY11 
cDNA  inserts. SY11  is  a  2.1-kb 
insert  and  it  included  5'  and  3' 
untranslated  regions  (small Mrs). 
SY2  (1.7  kb)  and  SY10  (1.6  kb) 
represented  DNA  inserts  with 
,~95%  overlap. Neither  SY2  nor 
SY10 was flanked by an untranslated 
stretch ofDNA. (b and c) Secondary 
structure  predictions  for  SY2 
(Golgin-160) and SY11 (Golgin-95) 
are illustrated in b and c, respectively. 
The  secondary  structure  was 
predicted using the program Peptide 
Structure  (47).  The  structure 
predicted for a domain is denoted 
by the position of the line (turns, 
ol-helices, B-sheets).  The sequence 
analysis shows that SY2 (b) does not 
have any/3-shect  structures and is 
exclusively  an or-helical molecule. 
SYll  (c)  is  predominantly  an (x- 
helical  model with  some/~-sheet 
structure.  Special features  of the 
proline-rich domain, glutamic acid- 
rich  domain,  coiled-coil  (leucine 
zipper) motif, and a single putative 
glycosylatinn  site identified in Fig. 
3 are indicated. (d) Amino add com- 
parison of SY11 and SY2 using Gap 
alignment.  SY2 and SY11 demon- 
strate 22%  sequence identity  and 
43%  sequence similarity￿9 
79-kD Golgi antigen reacted with antibodies from a patient 
with an overlap syndrome of SLE and polymyositis and rheu- 
matoid arthritis, respectively  (7, 9).  There are some differ- 
ences between  the antigens described in these reports  and 
ours. First, the molecular masses of the native Golgi proteins 
identified in our study and theirs are different. In addition, 
the antigen in the study of Rossie et al.  (7) was extracted 
from tissue culture cells  after  treatment  with 0.1  N  HC1. 
This is distinctly different from our antigen, which is resis- 
tant to 0.1 N  HC1 treatment (4). Indeed, when HEp-2 cells 
were treated in this manner,  the fluorescence was subjectively 
enhanced. Perhaps another protein that is extracted under these 
conditions  partially masks an epitope on our protein in situ. 
In addition,  although our antigens can be detected  in the 
soluble fraction ofceUs, the majority of our proteins are found 
in the insoluble fraction (data  not shown).  Similarities be- 
tween our antigens  and the 65-kD protein include resistance 
to detergent extraction, sensitivity to trypsin treatment, and 
preservation  of staining after  paraformaldehyde fixation. 
An interesting  feature of golgin-95  is the presence  of a 
coiled-coil motif (leucine zipper) characterized by six repeats 
of leucine residues at every seventh position (55). This motif 
is formed by two parallel amphipathic o~-helices, which struc- 
turally resembles a coiled-coil (56).  Coiled-coil  motifs have 
been noted in other autoantigens, including 52-kD SS-A/Ro 
(57) and the 80/86-kD  Ku (58) autoantigens  that react with 
autoantibodies  present  in SLE and Sj6gren's  syndrome  sera 
(reviewed in reference  3). The leucine zipper motif has also 
been described in a number of other prokaryotic and eukary- 
otic proteins,  most  notably  products  of nuclear  oncogenes, 
including c-fos and c-jun (59),  viral fusogenic proteins (60, 
61), and the envelope glycoproteins of HIV1 and other viruses 
56  Cloned Golgi Complex Autoantigens Table  1.  Characteristics  of Golgin-95 and Golgin-160 
Golgin-95  Golgin-160 
(SYll)  (SY2/SY10) 
Sequence data: 
Polypeptide molecular mass (kD) 
No. of amino acids 
Physical Measurements: 
In vitro  translated product molecular mass (kD) 
Protein band: MOLT4  +  Hep-G2 cells 
Sequence Similarities ("~20%): 
EMBL/GenBank  accession no. 
70  58.7 
620  579 
95  60 
95  160 
Heavy chain myosin  Heavy chain myosin 
Kinesin  USO1 
P,  estin  150-kD 
NUM 1  dynein-associated 
polypeptide 
LO6147  LO6148 
Figure  6.  Immunofluorescence localization of golgin-95 and gdgin- 
160. Anti-Golgi  antibodies from the prototype serum (SY) at~nity purified 
with XZap recombinant protein SY2 (a) or SYll (c) colocalized with rabbit 
antibodies raised against the golgin-160 (b) or golgin-95 recombinant pro- 
teins (d), respectively. The binding of afl:lnity-pudfied anti-SYll was traced 
with fluorescein-conjugated  goat anti-human antibodies and the binding 
of rabbit antibodies was traced with rhodamine-conjugated  goat anti-rabbit 
antibodies;  x400. 
(62). Although proteins with leucine zippers are able to bind 
DNA and are thought to be predominantly regulatory in 
their function (63),  this motif also mediates the dimeriza- 
tion of certain transactivators  (53,  64),  and is essential for 
recombination of certain viral proteins (65) and oligomeriza- 
tion of viral epitope proteins (61, 66, 67). Unlike golgin-95, 
some proteins with leucine zipper motifs contain a domain 
of 30-35 amino acids with a high ratio of the basic amino 
acids arginine and lysine, which are immediately adjacent to 
the putative zipper structure (55). 
Golgin-95 has a stretch of acidic residues from amino acids 
322 to 333. Consecutive stretches of acidic amino acid residues 
have been described in other autoantigens, including NOR-90 
(human upstream binding factor [hUBF]) (68), high mobility 
group protein I (HMG-1), centromere protein B (CENP-B), 
and nucleolin (reference 69 and references therein). Although 
the role of these sequences is not clear, it is likely that these 
stretches  are responsible for binding to cationic molecules. 
The Golgi complex, localized in the perinudear region of 
most mammalian cells, consists  of stacks  of membranous 
cisternae with functional and topological polarity (for reviews 
see references 14 and 15). The processing, maturation, and 
sorting of secretory and membranous proteins take place in 
this organelle.  Many of the specific enzymes responsible for 
the sequential modification of proteins passing through the 
Golgi complex have been characterized. Although consider- 
able detail about these enzymes is known, the mechanisms 
by which proteins are transported and sorted in the Golgi 
complex remain unclear. 
57  Fritzler et al. Figure 7.  Immunoblot analysis  of HepG2 whole cell extracts separated 
on 10% get SDS-PAGE and probed using rabbit antisera raised against 
golgin-160 and golgin-95.  The rabbit antisera diluted 1:100 show reac- 
tivity with proteins of similar molecular mass as the prototype serum (SY) 
diluted 1:50. Rabbit antibodies raised against SY2 (lane I) react with a 
160-kD protein that has the same molecular mass as the fainter upper band 
reacting with the prototype serum (lane 2). Rabbit antibodies raised against 
SYll (lane 3) react strongly with a 95-kD protein that has the same mo- 
lecular mass as a band recognized by the prototype  serum (lane 2). Lane 
4 represents the reactivity of a rabbit serum (1:50) 2 wk after immuniza- 
tion with SY10. Lane 5 was probed with an immune rabbit serum 2 wk 
after a boost with the recombinant  SY10 protein. This serum reacted with 
the 160-kD protein and several other lower molecular mass proteins. Lanes 
6 and 7 are preimmune rabbit serum and normal human serum, respectively. 
Recent evidence suggests that important molecules in this 
process are four high molecular mass coat proteins (COPs: 
or-COP,  160 kD;  B-COP,  110 kD;  "y-COP, 98  kD;  and 
fi-COP, 61 kD) that are major constituents of the nondathrin- 
coated vesicles (24). These proteins are associated with sev- 
eral other lower molecular mass (20-29-kD) proteins in the 
cytosol (23), bind reversibly to membranes of the Golgi com- 
plex, and exist as a high molecular mass complex  in the cytosol 
referred to as the "coatomer" (23, 24, 70). B-COP displays 
homology with the human clathrin-coated vesicle protein 
B-adaptin (24, 25). B-COP does not bear sequence similarity 
to kinesin or other microtubule-associated proteins (MAPs), 
nor does it have a transmembrane or other obvious target 
sequences (25). 
BFA, a drug that blocks intracellular transport, blocks the 
binding of B-COP to Golgi membranes producing a charac- 
teristic  pattern of immunofluorescence (71). In our study, 
we have noted similar effects of BFA on the intracellular dis- 
tribution of golgin-g5 and golgin-160. Taken together, these 
observations  suggest that golgin-95 and golgin-160 may be 
structurally and functionally related to the COPs. However, 
they do not have sequence similarity to B-COP or the adaptins, 
and do not bear the nonapeptide SLGEIPIVE described by 
Serafini et al. (24) or the putative microtubule-binding  motif 
KKEX motif in B-COP suggested by Duden et al. (25). A 
notable feature  of golgin-95 is  the sequence  similarity to 
microtubule proteins and, like B-COP, the absence of a trans- 
membrane or signal  sequence. 
It is possible that golgin-95 and golgin-160 are function- 
ally and structurally related because they share >43% sequence 
similarity and 22.5% sequence identity over a stretch of 618 
amino acids. In this regard, it is interesting that golgin-95 
and golgin-160 showed significant sequence similarity to several 
cytoskeleton-related proteins, including kinesin (72), the 150- 
kD dynein-associated  protein (73),  the myosin family pro- 
teins (heavy chain myosin, tropomyosin), and desmin. Kinesin 
is a microtubule-stimulated  ATPase (74, 75) and a likely motor 
protein for organdie transport along microtubules. The se- 
quence similarity of the golgins with these proteins is only 
~21%, but the aligned sequences span >300 amino acids in 
or-helical domains of these proteins. This suggests that the 
Golgi complex has unique motor proteins that are part of 
the myosin family. Another observation that supports this 
conclusion is that golgin-160 has sequence similarity to the 
yeast cytoskeleton-related protein USO1. It has been demon- 
strated that USO1 is required for protein transport from the 
endoplasmic reticulum to the Golgi apparatus (76). 
In summary, autoantibodies from a patient with SLE have 
been used to identify, done, and sequence two apparently 
related Golgi-associated proteins having molecular masses of 
95 and 160 kD. We have designated these proteins golgin-95 
and golgin-160. The function(s) of these two proteins is un- 
known. Based on the analysis of the sequences of these pro- 
teins and the effects of BFA on their distribution, several pos- 
sibilities  can  be  considered.  First,  these proteins may be 
kinesin-like motor proteins that have a role in the transport 
of vesicles from the endoplasmic reticulum to the Golgi com- 
plex or within the Golgi stack. Second, both proteins may 
form a cytoskeletal structure that is the framework for trans- 
port of Golgi vesicles. Sequence similarity of the cloned pro- 
teins to cytoskeleton-related proteins supports this possibility. 
The deduced secondary structure suggests a predominantly 
coiled-coil  structure. Third, golgin-95 may be a structural 
protein within the Golgi complex responsible for protein trans- 
port. The presence of a leucine zipper, and stretches of acidic 
residues, is consistent with features of a coat protein. This 
is further substantiated by observations that the behavior of 
both proteins is similar to B-COP after BFA exposure. Studies 
using a number of cell biology and molecular tools can help 
determine the more precise roles of these proteins in the fu- 
ture. In the meantime, sera from patients with SLE continue 
to provide valuable reagents in the study of immune responses 
and the structure and function of key cellular  organelles. 
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of in vitro translation and transcrip- 
tion products of SYll and SY2. In 
vitro translation products derived 
from the SYll or SY2 plasmid tem- 
plates linearized with SacI restric- 
tion enzyme and transcribed with 
T3 or T7 RNA polymerase.  The 
[3sS]methionine-labeled  in  vitro 
translated products were incubated 
with rabbit or human serum and the 
antigen-antibody  complexes  ad- 
sorbed to protein A-Sepharose. The 
complexes were separated by SDS-PAGE and the dried gel was processed and exposed to 
x-ray film to trace the bound antigen. (a) The translation product [3SSlmethionine-hbeled 
SY2 (lane I) migrated at 65 kD with smaller translation products also observed.  The 
65-kD [3sS]methionine-hbeled  in vitro translated product was not immunoprecipitated 
by preimmune rabbit serum (lanes 2 and 5) but it was by antibodies from rabbits immunized 
with the SY2 recombinant protein (hnes 3 and 4) and rabbits immunized with SY10 
(lanes  6  and  7).  The  prototype serum  SY  (lane  8)  and another  human  anti-Golgi 
serum (lane 9) did not immunoprecipitate the in vitro translated SY2 protein. (b) SYll 
(lane I) migrated at 95 kD with smaller translation products migrating at 68-94 kD also 
observed.  The 95-kD in vitro translation product was not immunoprecipitated by pre- 
immune rabbit serum (lane 2), but was immunoprecipitated by immune rabbit serum 
(lane 3),  the prototype serum SY  (lane 4),  and another anti-Golgi serum (lane  5). 
(c and d) Immunoblot analysis  of purified SY2 and SYll recombinant proteins extracted from 
inclusion bodies with 8 M urea and ~-mercaptoethanol and separated on a 10%  SDS- 
polyacrylamide  gels. Human antibodies to golgin-160 (c, lane I) and golgin-95 (d, lane I) 
and the prototype serum (c and d, lane 2) showed reactivity  with an ,,~70-kD recombinant 
SY2 (c) and an ~100-kD recombinant SYll (d). Similar reactivity was observed with 
affinity-purified  anti-SY2 (c, lane 3) and anti-SY11 (d, lane 3), and sera from rabbits im- 
munized with SY2 (c, lane 4) and SYll (d, lane 4). Normal human serum (c and d, lane 5) 
did not react with the recombinant proteins. 
Figure  9.  Effects  of  BFA  on  the  Goigi 
apparatus.  BFA at 7.5/~M was added to log- 
arithmic-growing HEP-2 cells in culture. At 
selected time intervals,  slides were removed, 
fixed, and processed for indirect immunofluo- 
rescence using affinity-purified  anti-SYll. (a) 
Time 0, demonstrating clearly defined Golgi 
organization; (b) 2 min after BFA, the Golgi 
antigen shows early signs ofredisttibution; (c) 
at 5 min, there is loss of staining in the Golgi 
region; (d) at 15 min, there is more loss of the 
lamellar Golgi antigen with apparent redistri- 
bution to the cytoplasm; (e) at 30 min, there 
is virtual loss of Golgi staining; (/) 90 min after 
BFA media was removed  and replaced  with 
fresh media, there is a restoration of the staining 
in vesicular and lamellar structures consistent 
with the Golgi staining. 
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